Poster Sessions

PS-01-001: Accounts of circulating tumor cells and ctc clusters with pd-l1 expression in sarcoma patients
Jayant Khandare, India
Abstract

PS-01-002: Improved isolation method to increase the purity of salivary exosomes for biomarker discovery in pancreatic cancer
Silvia Rocchiccioli, Italy
Abstract

PS-01-005: Urine circulating tumor dna analysis in bladder cancer using a targeted ngs panel
Chiara Nicolazzo, Italy
Abstract

PS-01-006: Real-time monitoring of circulating tumor cells in patients with pancreatic ductal adenocarcinoma. preliminary results of the french multicentric panlipsy study
Thomas Bardol, France
Abstract

PS-01-007: Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients
Kathrin Niedermayer, Germany
Abstract

PS-01-008: Circulating tumor dna sequencing for very early molecular evaluation of response to immune checkpoint blockade in patients with hodgkin lymphoma
Jan-Michel Heger, Germany
Abstract

PS-01-009: Smart biosurface® technology for prostate cancer detection and risk stratification through ctc enumeration and biomarker expression profiling
Roberta Carbone, Italy
Abstract

PS-01-011: Bladimirplus: a precise, multimodal, urine-based tool for non-invasive prediction of immunotherapy response in bladder cancer
Alvaro Martin De Bernardo Abellan, Spain
Abstract

PS-01-012: Advances in liquid biopsy for glioblastoma diagnosis and monitoring through nucleosome epigenetic modifications tracking
Marielle Herzog, Belgium
Abstract

PS-01-013: Multimodal analysis of plasma ctdna  is an independent prognostic marker of survival  in ovarian cancer: the mito 16a/mango ov2 clinical trial experience.
Sergio Marchini, Italy
Abstract

PS-01-014: Sarcoma classification by analyzing cell-free dna methylation profiles
Florian Janke, Germany
Abstract

PS-01-015: Non-invasive circulating tumor dna analyses for diagnosis and monitoring of treatment response in hodgkin lymphoma.
Emma Tham, Sweden
Abstract

PS-01-016: Self-supervised learning and human-in-the-loop methods for detection and differentiation of circulating tumor cells in liquid biopsy data
Hümeyra Husseini-Wüsthoff, Germany
Abstract

PS-01-017: Positive pre-debulking ctc status predicts worse surgery outcome in ovarian cancer patients
Annabelle Lobermeyer, Germany
Abstract

PS-01-018: Methylation and mutational analysis of circulating tumour dna in non-small cell lung cancer
Therese Grönqvist, Sweden
Abstract

PS-02-001: The survive study – standard surveillance vs. intensified liquid biopsy-based surveillance in early breast cancer survivors
Wolfgang Janni, Germany
Abstract

PS-02-002: Automated machine learning for breast cancer methylation biomarker discovery: a data-driven approach to be implemented in liquid biopsy
Ekaterini A. Chatzaki, Greece
Abstract

PS-02-003: Lymphovista - a validated platform for genotyping and mrd assessment in different types of lymphoma
Julia Mattlener, Germany
Abstract

PS-02-004: The survive heroes study: targeting molecular relapse in breast cancer
Wolfgang Janni, Germany
Abstract

PS-02-005: Methylation patterns in cell-free dna for pan-cancer detection
Alvida Qvick, Sweden
Abstract

PS-02-006: Developing a methylation-sensitive restriction enzyme-droplet digital pcr assay for the identification and monitoring of non-small cell lung cancer
Pim Rozendal, Netherlands
Abstract

PS-02-007: Personalized analysis of circulating tumor dna as a sensitive biomarker in non-hodgkin lymphoma
Raghda R. Ibrahim, Sweden
Abstract

PS-02-008: Unraveling metastatic mechanisms: from circulating tumor cell detection to molecular insights
Kyungsoo Kim, Korea
Abstract

PS-02-009: Tumor-agnostic detection of circulating tumor dna in patients with advanced pancreatic cancer using targeted dna methylation sequencing and cell-free dna fragmentomics
Oddmund Nordgard, Norway
Abstract

PS-02-010: Cell-free dna methylation detection in small plasma volumes using bisulfite-free multiplex digital pcr demonstrated in an early-onset colorectal cancer pilot study
Judith Sum, Germany
Abstract

PS-02-011: Liquid biopsy-based detection of bladder cancer using soluble immune checkpoints
Jessica Carlsson, Sweden
Abstract

PS-02-012: Libelule: a randomized phase 3 study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer
Aurélie Swalduz, France
Abstract

PS-02-013: Detection rate for esr1 mutations is higher in circulating-tumor-cell-derived genomic dna than in paired plasma cell-free dna samples as revealed by ddpcr
Aliki Ntzifa, Greece
Abstract

PS-02-014: Harnessing aqueous humor circulating tumor dna for retinoblastoma stratification
Stefanie Volz, Germany
Abstract

PS-02-015: Harmonized liquid biopsy precision medicine platform for molecular tumor boards (hilib-mtb)
Eva Dazert, Germany
Abstract

PS-02-016: Monitoring response to neoadjuvant therapy using a combination of circulating tumor dna and circulating tumor cells: a prospective study in patients with inflammatory breast cancer
Jennifer Chen, United States
Abstract

PS-02-017: Implementation of a novel spectral flow cytometry-based theragnostic test for circulating tumor cells in breast cancer
Stella Autenrieth, Germany
Abstract

PS-02-018: Establishing an academic hospital based liquid biopsy platform for mrd testing in breast cancer patients
Mark Basik, Canada
Abstract

PS-02-019: Full spectrum isolation technique-based circulating tumor cells and circulating cancer associated fibroblasts analysis to maximize early cancer diagnosis
Hyeongjung Woo, Republic of Korea
Abstract

PS-03-001: Unraveling the epitranscriptomic code: a breakthrough in early cancer detection
Alexandre David, France
Abstract

PS-03-002: Cell-free dna methylation profiling for diffuse large b-cell lymphoma subtyping via whole-genome enzymatic methyl sequencing
Daniyar Karabayev, Finland
Abstract

PS-03-003: Improved detection of residual disease in solid tumors via combined circulating tumor cell and cell-free dna profiling
Vineet Datta, India
Abstract

PS-03-004: Enspyre mrd: a novel enrichment approach for ultra-low variant detection with reduced sequencing requirements
Barnaby Balmforth, United Kingdom
Abstract

PS-03-005: Bridging artificial intelligence and liquid biopsy in cancer research: methodological approaches
Brune De Dreuille, Spain
Abstract

PS-03-006: Advancing Multi-Cancer Early Detection: High-Performance Cell-Free Rna Profiling With The Flomics Liquid Biopsy Platform
Marc Weber, Spain
Abstract

PS-03-007: Dynamic Changes In Bcma Levels: Implications For Assessing Therapeutic Outcomes In Multiple Myeloma
Elisabetta Pingitore, Italy
Abstract

PS-03-008: Liquid Biopsy: Measuring Circulating H3K27Me3-Nucleosomes In Lung Cancer Patients Is A Strong Prognostic Biomarker And A Potential Aid In Treatment Selection
Marielle Herzog, Belgium
Abstract

PS-03-009: Prognostic Significance Of Early On-Treatment Evolution Of Circulating Tumor Dna In Advanced Er+/Her2- Breast Cancer
Aaron Mamann, France
Abstract

PS-03-010: Fragmentomics: An R Package For Integrating Cell-Free Dna Fragment Features With Mutational Status To Support Liquid Biopsy Interpretation
Killian Maudet, France
Abstract

PS-03-011: Multi-Omics Approaches For Early Cancer Detection In Serial Liquid Biopsy Samples Of Cancer Predisposition Patients
Benedikt Kirchner, Germany
Abstract

PS-03-012: Liquid biopsy analysis of the serum exosomal micro-rna signature in vulvar carcinoma may benefit the diagnosis, prognosis of survival and predict hpv-positivity
Friederike Borchardt, Germany
Abstract

PS-03-013: Deciphering the diagnostic potential of non-coding rnas for the detection of pancreatic ductal adenocarcinoma through liquid biopsies
Hadas Volkov, Israel
Abstract

PS-03-014: Ultra-sensitive and multiplex mutation detection of tert and idh mutaionts in glioma patients
Lei Chen, Sweden
Abstract

PS-03-015: Flow cytometer-enabled multiplex superrca mutation assay in a single portion of circulating tumor dna (ctdna) sample
Lei Chen, Sweden
Abstract

PS-03-016: Comparative analysis of circulating tumor cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy
Simon Joosse, Germany
Abstract

PS-03-017: Validation of a cancer early-detection assay on liquid biopsies using dna methylation
Ludovic Boytard, Belgium
Abstract

PS-03-018: Experiences gained from real-world clinical testing of cancer patient plasma, using a highly sensitive, personalized circulating tumor dna assay
Christopher Smith, United Kingdom
Abstract

PS-03-019: Unveiling the clinical relevance of circulating tumour cells in lung cancer patients
Sofia Fernandes, Portugal
Abstract

PS-04-001: Monitoring of molecular response during immunotherapy by circulating tumor dna using patient-tailored assays in non-small cell lung cancer
Johanna Svensson, Sweden
Abstract

PS-04-002: Evaluation of cost savings associated with liquid biopsy in minimal residual disease-negative stage ii colon cancer patients
Valentino Martelli, Spain
Abstract

PS-04-003: Improved tumor-type informed compared to tumor-informed mutation tracking for ctdna detection and microscopic residual disease assessment in epithelial ovarian cancer
Mehdi Ben Sassi, France
Abstract

PS-04-004: Dynamic precision medicine: a new paradigm for minimal residual disease
Robert Beckman, United States
Abstract

PS-04-005: Circulating tumor cell vitality during and after radiotherapy mirrors treatment response in cancer patients
Harriet Wikman, germany
Abstract

PS-04-006: Decoding Minimal Residual Disease In Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Omic Approach
Valentino Martelli, Spain
Abstract

PS-04-007: Early detection of disease relapse in patients with operable breast cancer by circulating tumor dna monitoring.
Kjersti Tjensvoll, Norway
Abstract

PS-04-008: Individualized longitudinal tumor-informed ctdna monitoring in advanced cancers using ots-probes dedicated to digital pcr
Satoshi Nishizuka, Japan
Abstract

PS-04-009: Minimal invasive detection of circulating biomarkers in pediatric cancer patients undergoing chimeric antigen receptor t-cell therapy
Esther Wahlbrink, Germany
Abstract

PS-04-010: Circulating evs in progressive nen g3 patients: potential predictors of resistance to combined immune checkpoint inhibitor/tyrosine kinase inhibitor therapy?
Esther Mettler, Germany
Abstract

PS-04-011: Single-cell transcriptome data enable the identification of novel potential circulating tumor cell-specific markers in non-small cell lung cancer
Karen Wiegand, Germany
Abstract

PS-04-012: Tracking melanoma: circulating melanoma cells (cmcs) and immune changes during immunotherapy
Claudia Dompe, Poland
Abstract

PS-04-014: Customized immunotherapy using liquid biopsy and research data integration for non-small cell lung cancer : the cure project
Catherine Alix-Panabières, France
Abstract

PS-04-015: Mapping the surfaceome of circulating colon tumor cells to discover immune evasion mechanisms and therapeutics targets
Doryan Masmoudi, France
Abstract

PS-04-016: Soluble immune checkpoint proteins as predictive biomarkers for lymph node metastasis in penile cancer
Sabina Davidsson, Sweden
Abstract

PS-04-017: Added value in detecting actionable mutations for matched plasma-based vs. tissue next-generation sequencing in advanced NSCLC: a retrospective analysis
Véronique Hofman, France
Abstract

PS-04-018: Stool host transcriptomics enables diagnostic and molecular characterization of colorectal cancer
Keren Bahar Halpern, Israel
Abstract

PS-05-001: Laser isolation of circulating tumor cells in liquid biopsy
Carlos Molpeceres, Spain
Abstract

PS-05-002: Cellsearch and accept: detection of circulating tumor and hybrid cells to improve prognostic accuracy in metastatic colorectal cancer
Michela De Meo, Italy
Abstract

PS-05-003: Analysis of circulating cancer-associated fibroblasts and circulating tumor cells in advanced melanoma patients using continuous centrifugal microfluidics technology
Kim-Lea Reese, Germany
Abstract

PS-05-004: Optimized library preparation kit and workflow for improving cfdna sequencing sensitivity
Tina Han, USA
Abstract

PS-05-005: Malarial protein var2csa improves circulating tumor cell detection from triple-negative breast cancer patients
Deniz Dilay Karayel, Germany
Abstract

PS-05-006: Recombinant nucleosomes as promising key reference materials for liquid biopsy next-generation sequencing.
Priscilla Van Den Ackerveken, Belgium
Abstract

PS-05-007: A versatile method for circulating cell-free dna methylome profiling by reduced representation bisulfite sequencing
Anxhela Zaka, Belgium
Abstract

PS-05-008: Fragmentomics analysis to enhance ctdna based risk stratification in aggressive b-cell lymphoma
Jessica Schneider, Germany
Abstract

PS-05-009: A beta pancreatic methylation biosignature for the diagnosis & prediction of type 2 diabetes mellitus.
Ekaterini A. Chatzaki, Greece
Abstract

PS-05-010: Characterizing adipocyte cell free dna and its contribution to immune activation
Ekaterini A. Chatzaki, Greece
Abstract

PS-05-011: Enrichment and molecular profiling of circulating melanoma cells: an optimized microfluidic-based workflow
Alessandro Francesco Piazza, Italy
Abstract

PS-05-012: Alma platform: an agnostic multi-modal liquid biopsy approach for enhanced mrd detection and therapy monitoring across multiple cancer types
Lara Paracchini, italy
Abstract

PS-05-013: Ctc-finder® a reagent-based kit to sort, count, and recover culturable circulating tumor cells (ctc) from human whole blood with very high purity, sensitivity and specificity
Clément Auger, France
Abstract

PS-05-014: Detection of low-frequency mutations in plasma ctdna: performance assessment of a targeted ngs ivd assay in metastatic breast cancer
Giulia Cursano, Italy
Abstract

PS-05-015: Development of a single-cell methylation workflow to understand the biology of circulating cells in early-stage non-small cell lung cancer
Hannah Sheedy, United Kingdom
Abstract

PS-05-016: Spatial and temporal tumor heterogeneity representation in liquid biopsies of pediatric precision oncology patients
Samuel Zabel, Germany
Abstract

PS-05-017: Development of a preanalytical workflow for liquid biopsy research from urine
Markus Wolf, Germany
Abstract

PS-05-018: Cross-platform analysis of multiplex protein assays in serum and plasma of cancer patients
Aoife Gahlawat, Germany
Abstract

PS-06-001: Evaluating the complementarity of ngs and dpcr assays for ctdna-based esr1 mutation detection in hr+/her2- metastatic breast cancer
Riccardo Adorisio, Italy
Abstract

PS-06-002: Millions of parallel reactions enabled by centrifugal microfluidic array technology for high-dynamic-range digital assays in liquid biopsy
Peter Juelg, Germany
Abstract

PS-06-003: Enhanced detection of esr1 mutations in breast cancer: validation of the galeas upcr:esr1 kit on multiple commercially available reference standards.
Charlotte Morgan, United Kingdom
Abstract

PS-06-004: Genetic profiling of circulating tumor cells from the cerebrospinal fluid of breast cancer patients with leptomeningeal metastasis
André Franken, Germany
Abstract

PS-06-005: Liquid biopsy analysis of advanced cancer patients – a real-life perspective of actionable variants
Thomas Kessler, Germany
Abstract

PS-06-006: Development and multi-site evaluation of an esr1 liquid biopsy reference material for metastatic breast cancer resistance monitoring
Krystyna Nahlik, USA
Abstract

PS-06-007: Comparative value of using an ultra-fast NGS (Oncomine Precision Assay) on site, on matched liquid biopsy testing (LBx) and tissue biopsy testing (TBx) in advanced lung cancer patients. A pilot study from a single center (IHU RespirERA, Nice, France)
Guylène Rignol, France
Abstract

PS-06-008: Evaluation of bridge capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients
Jukka Laine, finland
Abstract

PS-06-009: Comparison on-site between liquid biopsy pillar biosciences ngs panels and tissue biopsy oncomine precision assay (thermo fisher scientific) in advanced non-small cell lung cancer at diagnosis. a preliminary retrospective study from a single center (ihu r
Caroline Lacoux, France
Abstract

PS-06-011: Infrared molecular fingerprinting – a new technological platform for cancer screening and diagnostics
Mihaela Zigman, Germany
Abstract

PS-06-012: A single ngs assay for the simultaneous detection of igh translocations, copy number alterations and sequence mutations in circulating multiple myeloma cells (cmmcs)
Federica Sola, Italy
Abstract

PS-06-013: Equal-depth sequencing of white blood cells (wbc) and plasma from prostate cancer (pca) liquid biopsies (lbx) and association with clonal hematopoiesis (ch) confounders in clinically relevant genes.
Mehlika Hazar Rethinam, Switzerland
Abstract

PS-06-014: To biopsy or not to biopsy: a predictive model for liquid biopsy in advanced pancreatic cancer
Hampig Raphaël Kourié, Lebanon
Abstract

PS-06-015: Underweight, underdetected: does cachexia reduce liquid biopsy positivity in cancer?
Hampig Raphaël Kourié, Lebanon
Abstract

PS-06-016: Liquid biopsy for monitoring of ras status in metastatic colorectal cancer
Hampig Raphaël Kourié, Lebanon
Abstract

PS-06-017: Sample-To-Answer Analysis Of Cell-Free Dna Using Centrifugal Microfluidics And Multiplex Mediator Probe Digital Pcr - A Concept Study
Christoph Stärk, Germany
Abstract

PS-06-018: Proteomic And Functional Impact Of Breast Cancer-Derived Cell-Free Dna On Benign Breast Epithelial Cells
Ekaterini A. Chatzaki, Greece
Abstract

PS-07-002: Liquid Biopsy Of Intact Ctcs Detects Early Changes In Breast Cancer Tumor Biology To Guide Therapeutic Intervention
Triantafyllos (Fyl) Tafas, Connecticut, USA
Abstract

PS-07-003: Cfdna Reference Material: Mimicking Human-Like Profiles
Renu Datta, United Kingdom
Abstract

PS-07-004: Circulating Tumor Cells Isolation From Prostate Cancer Patients Using A New Microfiltration Device: Pilot Study And Potential Correlation With Psma-Pet Imagining Scan.
Jesus Rolando Delgado Balderas, Mexico
Abstract

PS-07-005: Ctdna monitoring in metastatic uveal melanoma patients treated with tebentafusp using mutation-agnostic multiplex ddpcr assays
Shufang RENAULT, France
Abstract

PS-07-006: Detection of met exon 14 skipping mutation by maldi-tof based liquid biopsy in non-small cell lung cancer
Bidisha Paul, Germany
Abstract

PS-07-007: Low-level variants present a challenge in the clinical interpretation of liquid-biopsy-based comprehensive genomic profiling for patients with solid tumors
Katharina Jonas, Austria
Abstract

PS-07-008: Unlocking the full potential of liquid biopsy with advanced cfdna extraction
Jordi Royes, France
Abstract

PS-07-009: Transcriptional profiles of circulating tumor cells reflect heterogeneity and molecular subtypes in advanced prostate cancer
Stefan Werner, Germany
Abstract

PS-07-010: D-dimers as prognostic markers in melanoma patients under immune checkpoint inhibition - a bicentre study
Tim Zell, Germany
Abstract

PS-07-012: Unraveling immune complexity in metastatic colorectal cancer: a step towards the development of circulating immune biomarkers
Elena Benidovskaya, Belgium
Abstract

PS-07-013: Presurgery ctdna clearance predicts response to neoadjuvant chemo-immunotherapy in advanced serous ovarian cancer
Paul Van Der Leest, Netherlands
Abstract

PS-07-014: Epilunar: epigenomic profiling of liquid biopsy and immunotherapy resistance in non-small cell lung cancer
Angel Díaz-Lagares, Spain
Abstract

PS-07-015: Canserv – providing cutting edge cancer research services across europe
Jens K. Habermann, Austria
Abstract

PS-07-016: Unveiling the extracellular vesicles potential for the early detection of resistance to immunotherapy in melanoma patients
Cristina Catoni, Italy
Abstract

PS-07-017: Pd-1 and pd-l1 gene expression analysis in peripheral blood mononuclear cells in non-small cell lung cancer: association with kras mutation status and patient prognosis
Kleita Michaelidou, Greece
Abstract

PS-07-018: Advancing biobanking in europe to foster cancer research
Jens K. Habermann, Austria
Abstract

PS-08-001: Single-cell rna sequencing in osteosarcoma: applications in diagnosis, prognosis, and treatment
Hampig Raphaël Kourié, Lebanon
Abstract

PS-08-002: Combination therapy of pi3k and egfr inhibitors in patient-derived gastroesophageal circulating tumour cell models
Jacqueline Holliday, Australia
Abstract

PS-08-003: Clinical impact of pd-l1, junb, and cxcr4 expression in circulating tumor cells and extracellular vesicles derived from triple negative breast cancer patients
Galatea Kallergi, Greece
Abstract

PS-08-004: Tracking clonal evolution in large b-cell lymphoma using ctdna sequencing
Julia Katharina Schleifenbaum, Germany
Abstract

PS-08-005: Repurposing artesunate for targeting cancer cells and circulating tumor cells (ctcs)
Galatea Kallergi, Greece
Abstract

PS-08-006: Assessment of trop2 and pdl1 expression on circulating tumor cells (ctcs) of patients with triple negative breast cancer
Sofia Agelaki, Greece
Abstract

PS-08-007: Functional characterization of pi3k c2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells
Manfred Jücker, Germany
Abstract

PS-08-009: Serial Circulating Tumor Dna (Ctdna) Assessment To Predict Treatment Response And Identify Genomic Evolution In Patients With Metastatic Breast Cancer (Mbc)
Mehlika Hazar Rethinam, Switzerland
Abstract

PS-08-010: Binding Of Extracellular Vesicles To Stretched Von Willebrand Factor Promotes Thrombosis
Yuanyuan Wang, Germany
Abstract

PS-08-011: A drug repurposing screen identified efficacious topoisomerase 2 (top2) inhibitors against mutant kras-driven colon cancer metastasis
Jit Kong Cheong, Singapore
Abstract

PS-08-012: Studying metastasis and immune-related mechanisms of oregano, graviola and cinnamon nanosuspensions against non-small cell lung carcinoma
Yamixa Delgado, Puerto Rico
Abstract

PS-08-013: High-Affinity Bcma-Targeting Peptides: Innovations In Therapeutic Strategies For Hematological Malignancies
Khushboo Fatima, Italy
Abstract

PS-08-014: Simsen personal – a personalized, tumor-guided sequencing platform for ultrasensitive ctdna detection in clinical trials
Niki Rostamzadeh, Sweden
Abstract

PS-08-015: Evaluating a tumor-agnostic methylation-based mrd assay in a real-world setting: the lb-clear study
Guy Froyen, Belgium
Abstract

PS-08-016: Association of circulating tumor cell dynamics with disease progression in stage i-iv melanoma
Jennifer Chen, United States
Abstract

PS-08-017: Whole genome sequencing of cell-free dna from metastatic breast cancer patients: a study of accuracy and response
Alexander Venzel Rudbeck, Denmark
Abstract

PS-08-018: Whole exome sequencing of circulating tumor dna to determine treatment response and detect recurrence in gastroesophageal cancer
Mikkel Møller Henriksen, Denmark
Abstract

PS-08-019: Malignant alliances: how circulating tumor cells and their extracellular vesicles orchestrate platelet education in the bloodstream
Zahra Eslami-Samarin, France
Abstract